Shaperon, a biotech firm listed on Kosdaq that specializes in developing immunotherapies, has announced its plans to establish a new subsidiary in the U.S. The subsidiary will be named Hudson Therapeutics Inc.

Shaperon will invest an initial capital of $2.3 million in Hudson Therapeutics and will directly hold a 100 percent stake in the company. Hudson Therapeutics will serve as the global clinical control tower for the parent company's lead pipeline and will be responsible for global licensing deals.

Shaperon has stated that the new subsidiary, Hudson Therapeutics, will be based in Boston, a major global pharmaceutical hub. The company plans to establish an additional office in Washington, D.C., to support global clinical development and ensure effective communication with the U.S. FDA. 

Shaperon also said it plans to establish a synthetic drug lab in Research Triangle Park in North Carolina.

"The Research Triangle Park is a high-tech research complex built around three universities -- North Carolina State University, Duke University, and the University of North Carolina," the company said "Notably, the research park it is open to foreign companies as well as U.S. companies, and leads the development of new technologies through active R&D cooperation between companies, research institutes, and universities."

Shaperon CEO Seong Seung-yong also said, "We expect the establishment of our U.S. subsidiary to be an important stepping stone for the successful global clinical trials and license deal of our drug pipeline."

The company will strive to achieve tangible results through more efficient and rapid business development and clinical trials by operating a local U.S. subsidiary, Seong added.